Cyfra 21 - 1
21.00 BGN
General information:
Cyfra 21-1 is found in the cells of lung tissue, the uterus and the gastrointestinal tract. It is used as an indicator of the degree of malignant degeneration and necrosis. Elevated levels of this tumor marker occur in polymorphonuclear carcinoma of the lung, cervical cancer, breast cancer, bladder cancer, ovarian cancer, esophagus cancer, and rectal cancer. Serum levels of the marker have been shown to decrease sharply after lung tumor removal, particularly after surgery. It is a very informative marker in lung cancer monitoring. In benign diseases, the etiology of an increased level of Cyfra 21-1 is observed in cirrhosis of the liver, chronic renal failure, bronchial asthma and tuberculosis. The main indications for the study of this marker is the monitoring of cancer of the uterus (especially the cervix) and polymorphonuclear lung cancer. The level of Cyfra 21-1 was generally the same in the serum of patients with non-malignant diseases, with small cell lung carcinoma (SCLC) and in the control group. Significantly higher levels of Cyfra 21-1 were noted in patients with non-small cell lung cancer (NSCLC), adenocarcinoma and squamous cell carcinoma of the lung. This confirms the high sensitivity and specificity of Cyfra 21-1 in the differential diagnosis of malignant and benign lung diseases, as well as SCLC and NSCLC. The sensitivity and specificity of Cyfra 21-1 in lung cancer was 57.7 and 91.9%, respectively. In squamous cell carcinoma of the lung (PRL), the sensitivity (76.5%) was higher than in adenocarcinoma (47.8%) and small cell lung carcinoma (32.1%).
Sample required:
Venous blood in morning in fasting